Evidence map›Paper›PMID 40641804›Full record

ReviewMolecular therapy. Nucleic acids2025

Deep learning in next-generation vaccine development for infectious diseases.

Manojit Bhattacharya, Yi-Hao Lo, Srijan Chatterjee, Arpita Das, Zhi-Hong Wen, Chiranjib Chakraborty

Abstract readReview
In one paragraph

Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Manojit BhattacharyaDepartment of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore, Odisha 756020, India.
Yi-Hao LoDepartment of Family Medicine, Zuoying Armed Forces General Hospital, Kaohsiung 81342, Taiwan.
Srijan ChatterjeeInstitute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-Do 24252, Republic of Korea.
Arpita DasDepartment of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal 700126, India.
Zhi-Hong WenDepartment of Marine Biotechnology and Resources, National Sun Yat-Sen University, #70 Lien-Hai Road, Kaohsiung 804201, Taiwan.
Chiranjib ChakrabortyDepartment of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal 700126, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The landscape of vaccine development was changed in the genomic era with the help of computer science. Computer-aided vaccine epitope selection has become a foundation of rational vaccine design. Similarly, artificial intelligence (AI) is quickly transforming the vaccine development landscape. Deep learning (DL), a subset of AI, is used in the landscape of vaccine development in terms of its algorithms, tools, and technologies. This review article discussed the developmental history of the modern era of vaccine development strategies using both immunoinformatics with DL models, identification strategies of T cell epitopes and B cell epitopes through immunoinformatics and DL models, vaccine constructs development strategies using linker and adjuvant, and characterization strategies of vaccine construct using bioinformatics and immunoinformatics. Similarly, the article discusses different tools and technologies, from epitope mapping and vaccine construct development to characterization. Again, it also highlighted recent paradigm shifts, DL-based strategies in vaccine development, and different DL-based tools used for epitope mapping and vaccine construct development. However, integrated frameworks connecting the bioinformatics and DL approaches are rapidly progressing, which are necessary for DL-assisted epitope prediction and the subsequent steps for vaccine development. DL-assisted vaccine development is rapid and cost-effective, changing the scenario of next-generation vaccine development very fast.

Indexed as

deep learningimmunoinformaticsinfectious diseasesMT: Bioinformaticsnext-generation vaccine

Identifiers

PMID40641804
PMCPMC12242420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.